Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

Concerns about the company's future growth are likely keeping investors away.

The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Metsera stock was tumbling on Monday after Pfizer agreed to buy the weight-loss drug start-up in a deal that could end up ...

Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more ...

Markets have turned upbeat amid optimism that the 39-day US shutdown could soon come to an end, after a weekend of dealmaking in Washington. A new bill quickly advanced in a key S ...

Major U.S. equities indexes rose Monday afternoon amid optimism Congress could soon agree on a spending plan to end the ...

Pfizer wins Metsera after antitrust warning derails Novo's $9B bid; investors reward financial discipline over deal chasing.

Metsera said that Pfizer will pay up to US$86.25 a share, including US$65.60 a share in cash initially, plus potential additional payments of up to US$20.65 a share for hitting certain milestones.

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...